Full Breakdown
Rising Prescription Drug Prices Amid Trump's Policies
10/1/2025, 10:11:31 AM
Overview of Price Increases
Since President Donald Trump took office in January 2025, the prices of 688 prescription drugs have increased significantly, according to a report by Senator Bernie Sanders (I-Vermont). The report highlights that 25 of these drugs have more than doubled in price, with a median increase of 5.5%. Notably, Eton Pharmaceuticals raised the price of Galzin, a medication for Wilson's disease, by over 1,500%, from $5,400 to $88,000 annually, while the same drug costs $1,400 in the United Kingdom. The report indicates that more than one in three of the affected drugs are used to treat serious conditions such as neurological diseases, cancer, or cardiovascular diseases.
Trump's Tariff Policy and Its Implications
On September 25, 2025, Trump announced a 100% tariff on branded and patented pharmaceutical products imported into the United States, effective October 1. This policy aims to incentivize pharmaceutical companies to establish manufacturing plants in the U.S. However, experts warn that this could lead to a significant increase in drug prices for consumers. The tariff is expected to impact both manufacturers and patients, as companies may pass the increased costs onto consumers. Suleman Daya, a pharmacist, expressed concern that the tariff would lead to higher medication costs for low-income patients, particularly refugees who rely on affordable prescriptions.
Legislative Context and Criticism
In response to the rising drug prices, Sanders introduced the Prescription Drug Price Relief Act, which seeks to ensure that Americans pay no more than the median price for prescription drugs in other developed countries. Sanders criticized the Trump administration's approach, stating that it relies on "press releases and polite requests" rather than substantial legislative action. He emphasized the need for real measures to combat pharmaceutical industry greed.
Critics of Trump's policies argue that the tariffs and the administration's One Big Beautiful Bill Act, which includes significant cuts to federal healthcare, will exacerbate the affordability crisis for millions of Americans. The report warns that these cuts will make it increasingly difficult for individuals to afford necessary medications, leading to higher out-of-pocket costs and loss of coverage.
Conflicting Reports and Future Outlook
While Trump claims that his administration's actions will lower drug prices, experts remain skeptical about the effectiveness of these measures. Stacie Dusetzina, a prescription drug pricing expert, noted that the specifics of the Pfizer deal, which promises lower prices for Medicaid, remain unclear. Additionally, analysts predict that the tariffs could lead to higher insurance premiums and co-payments, further burdening consumers.
As the October 1 deadline approaches, the pharmaceutical industry faces pressure to adapt to the new tariff regime. The outcome of this policy will have significant implications for drug pricing and access to medications in the U.S., raising concerns about the potential for increased costs and reduced availability of essential drugs.
Verbatim Quotes
- “Millions of Americans take one of the 688 drugs that have increased in price since Trump entered office in January of this year,” — Sen. Bernie Sanders
- “Today we are turning the tide and reversing an unfair situation.” — Albert Bourla, CEO of Pfizer
- “If Trump is serious about making real change, he should work with Congress to make sure all Americans pay no more than people in other countries for prescription drugs.” — Sen. Bernie Sanders
- “The threat of a 100% tax on the cost of import makes them even more expensive.” — Industry Analyst
The ongoing developments in drug pricing policies under the Trump administration will continue to be a critical issue for American consumers, particularly those reliant on expensive medications.
